Q4 2025 · 13F-HR
GordonMD Global Investments LPholdings as filed
Filed 2026-02-17 · accession 0000919574-26-001152
$139.5M
Reported value
13
Positions
2025-12-31
Period end
The Brief · GordonMD Global Investments LP · Q4 2025
AI · grounded in 13F
GordonMD Global Investments LP established a new position in KYTX valued at $41.3M. The fund also initiated new stakes in TEVA for $24.0M and BLCO for $10.5M. Additional new positions include CRNX, AMGN, and RARE. The fund ended the period with 13 positions and total AUM of $139.5M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 501976104 | KYTX | KYVERNA THERAPEUTICS INC | $41.3M | 29.6% | 4,391,818 | Common | SOLE |
| 881624209 | TEVA | TEVA PHARMACEUTICAL INDS LTD | $24.0M | 17.2% | 769,550 | Common | SOLE |
| 071705107 | BLCO | BAUSCH PLUS LOMB CORP | $10.5M | 7.51% | 613,472 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $10.4M | 7.48% | 224,135 | Common | SOLE |
| 031162100 | AMGN | AMGEN INC | $7.6M | 5.45% | 23,212 | Common | SOLE |
| 90400D108 | RARE | ULTRAGENYX PHARMACEUTICAL IN | $7.6M | 5.43% | 329,101 | Common | SOLE |
| 877619106 | TSHA | TAYSHA GENE THERAPIES INC | $7.3M | 5.25% | 1,330,901 | Common | SOLE |
| 92764N102 | VIR | VIR BIOTECHNOLOGY INC | $5.6M | 4.02% | 930,317 | Common | SOLE |
| 87650L103 | TARS | TARSUS PHARMACEUTICALS INC | $5.5M | 3.91% | 66,680 | Common | SOLE |
| 45337C102 | INCY | INCYTE CORP | $5.4M | 3.86% | 54,500 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $5.0M | 3.57% | 28,587 | Common | SOLE |
| 747324101 | PYXS | PYXIS ONCOLOGY INC | $4.7M | 3.40% | 4,121,870 | Common | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC NEW | $4.6M | 3.32% | 170,307 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.